News | Breast Biopsy Systems | August 28, 2020

Updates to Hologic's Brevera Breast Biopsy System with CorLumina Imaging Technology

First and only system to combine tissue acquisition, real-time imaging verification and post-biopsy handling now features new functionality, simplified storage and improved waste management

Hologic, Inc., an innovative medical technology company primarily focused on improving women’s health, announced improvements to the Brevera Breast Biopsy System with CorLumina Imaging Technology, the world’s first and only breast biopsy solution to combine vacuum-assisted tissue acquisition, real-time imaging verification and advanced post-biopsy handling in one, integrated system.

August 28, 2020 — Hologic, Inc., an innovative medical technology company primarily focused on improving women’s health, announced improvements to the Brevera Breast Biopsy System with CorLumina Imaging Technology, the world’s first and only breast biopsy solution to combine vacuum-assisted tissue acquisition, real-time imaging verification and advanced post-biopsy handling in one, integrated system.

Since its launch in 2017, the Brevera system has shifted the way clinicians perform breast biopsies and verify that the targeted tissue samples have been acquired. The system streamlines the entire biopsy process from start to finish — with real-time imaging for verification of sample acquisition and automated post-biopsy specimen handling. These integrated features offer the potential to save facilities an average of 13 minutes per procedure to transform the patient experience and enhance workflow. In addition, they allow clinicians to remain by the patient’s side during the entire procedure, eliminating the need to leave the room to image and verify tissue samples, which often leads to lengthy procedure times and anxious patients, as well as interruptions to facility screening schedules.

“As a world leader in breast health, we take great pride in our commitment to constant innovation — informed by clinical research and customer feedback – to continuously expand and improve upon the performance of our products,” said Jennifer Meade, Hologic’s Division President, Breast and Skeletal Health Solutions. “The launch of the Brevera system represented a major transformation in breast biopsy, and we’re confident that the improvements we’ve introduced will further the system’s ability to enhance workflow, increase accuracy and improve the overall patient experience.”

To better meet clinician needs, the Brevera system features a reusable device driver and disposable needles to simplify storage and improve waste management. The system also features improvements that allow radiologists and technologists to better separate and verify target samples automatically, then transfer seamlessly to pathology with minimal handling to help maintain core integrity.

The Brevera system is designed for use with Hologic’s Affirm Prone biopsy guidance system. When paired together, the Brevera system and Affirm® system accelerate the speed and efficiency of prone biopsy procedures to further reduce the patient’s time under compression.

For more information: www.hologic.com

Related Content

A 37-year-old woman developed a new, palpable left supraclavicular lymphadenopathy lump five days after her first dose of the Moderna COVID-19 vaccine in the left arm. On the day of vaccination, the patient was asymptomatic. This is an example of how the vaccine can mimic cancer and swollen lymph nodes. Image used with permission of RSNA.

A 37-year-old woman developed a new, palpable left supraclavicular lymphadenopathy lump five days after her first dose of the Moderna COVID-19 vaccine in the left arm. On the day of vaccination, the patient was asymptomatic. This is an example of how the vaccine can mimic cancer and swollen lymph nodes. Read more about this case study. Image used with permission of RSNA.

Feature | Coronavirus (COVID-19) | May 03, 2021 | By Dave Fornell, Editor
While the mass COVID-19 vaccinat
A 63-year-old multiple #myeloma patient, with skeletal pain. New #FDG avid axillary #lymphadenopathy 62 days (9 weeks) after second #mRNA #vaccination dose. Image used with permission of the Radiological Society of North America (#RSNA)

A 63-year-old multiple myeloma patient, with skeletal pain. New FDG avid axillary lymphadenopathy 62 days (9 weeks) after second mRNA vaccination dose. Image used with permission of the Radiological Society of North America (RSNA)

Feature | Coronavirus (COVID-19) | April 29, 2021 | By Melinda Taschetta-Millane
ACR releases 13 new topics and five revised topics to support referring physicians and other providers in making the most appropriate imaging or treatment decisions
News | Radiology Imaging | April 26, 2021
April 26, 2021 — The American College of Radiology (ACR) released an update to its...
The Imagio Breast Imaging System combines laser light and sound with conventional ultrasound technology to provide fused functional and anatomic images (referred to as optoacoustic/ultrasound or OA/US) in real time, increasing confidence in diagnostic accuracy.

The Imagio Breast Imaging System combines laser light and sound with conventional ultrasound technology to provide fused functional and anatomic images (referred to as optoacoustic/ultrasound or OA/US) in real time, increasing confidence in diagnostic accuracy.

News | Breast Imaging | April 23, 2021
April 23, 2021 — The U.S.
A Norwegian study for the first time reveals benefit of the #PARP inhibitor #Olaparib in patients with early #breastcancer not harboring germline mutations

Getty Images

News | Radiation Therapy | April 22, 2021
April 22, 2021 — Targeted therapy in early stages of breas...
Women at high risk of breast cancer face cost-associated barriers to care even when they have health insurance, a new study has found.

Getty Images

News | Women's Health | April 22, 2021
April 22, 2021 — Women at high risk of breast cancer face cost-associated barriers to care even when they have health